Angioplasty or medical therapy in patients with documented ischemia

Original title: Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clinical trials. Reference: Stergiopoulos K el al. JAMA Intern Med 2013; DOI:10.1001/jamainternmed.2013

The amount in ischemic patients with stable coronary heart disease is associated with poor prognosis. However, it is unclear whether revascularization to reduce that amount also reduces ischemic events compared with medical treatment.

This meta- analysis included major works that randomized patients with stable coronary artery disease and demonstrated ischemia  to revascularization or medical treatment (MASS II , COURAGE , BARI 2D , FAME 2, etc.) . A total of 4064 patients, all with documented ischemia by stress test, gamma camera, echo stress or fractional flow reserve were analyzed. The endpoints included in the analysis were death from any cause, nonfatal myocardial infarction, urgent revascularization and angina. With a median follow-up of 5 years,  mortality rate from all causes was observed in the group receiving revascularization by angioplasty  versus  those who only received medical treatment  6.5 % and 7.3 % respectively (OR 0.90 CI 95% 0.71 to 1.16; p= ns) , nonfatal myocardial infarction 9.2 % and 7.6% (OR 1.24 CI 95% 0.99 to 1.56; p=ns) , urgent revascularization 18.3 % and  28.4 % (OR 0.64, CI 95% 0.35 to 1.17) and angina 20.3 % and 23.3 % (OR 0.91, CI 95% 0.57 to 1.44).

Conclusion:

In patients with stable coronary artery disease and documented ischemia, percutaneous revascularization does not seem to reduce events compared with medical treatment alone.

Editorial comment

This work, like all meta-analyzes, drag the limitations of the studies in which it was based. For example, ischemia was documented in all patients but as a binary variable. If we know that the greater ischemia increased mortality, why not also expect a different benefit with revascularization according to the amount. The same should be considered for symptoms; to worse major functional class a greater relief should be by revascularization. Finally the localization of the ischemic territory is taken into account in daily practice but has been difficult to differentiate in the works and should be taken into consideration. Perhaps some of these questions can be answered by the 8000 patients that ISCHEMIA study plans to include. 

SOLACI.ORG

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...